Midazolam & Doxepin Metabolite Reporting Immediate Update 12/12/2023
December 12, 2023
In December 2023, Alverno Laboratories announced the suspension of reporting quantitative values for alphahydroxymidazolam and desmethyldoxepin due to a technical issue with the assay. While the vendor works to resolve this, only qualitative reporting will be available. Despite this change, samples from patients taking Midazolam or Doxepin as prescribed will still be interpreted as "consistent." Healthcare providers with questions or concerns are encouraged to contact Alverno Central Laboratory for assistance from their Toxicologist.